Unknown

Dataset Information

0

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.


ABSTRACT: Breast cancer brain metastases (BCBMs) are common in patients with metastatic breast cancer and indicate a poor prognosis. These tumors are especially resistant to currently available treatments due to multiple factors. However, the combination of chimeric antigen receptor (CAR)-modified immune cells and oncolytic herpes simplex virus (oHSV) has not yet been explored in this context. In this study, NK-92 cells and primary NK cells were engineered to express the second generation of EGFR-CAR. The efficacies of anti-BCBMs of EGFR-CAR NK cells, oHSV-1, and their combination were tested in vitro and in a breast cancer intracranial mouse model. In vitro, compared with mock-transduced NK-92 cells or primary NK cells, EGFR-CAR-engineered NK-92 cells and primary NK cells displayed enhanced cytotoxicity and IFN-? production when co-cultured with breast cancer cell lines MDA-MB-231, MDA-MB-468, and MCF-7. oHSV-1 alone was also capable of lysing and destroying these cells. However, a higher cytolytic effect of EGFR-CAR NK-92 cells was observed when combined with oHSV-1 compared to the monotherapies. In the mice intracranially pre-inoculated with EGFR-expressing MDA-MB-231 cells, intratumoral administration of either EGFR-CAR-transduced NK-92 cells or oHSV-1 mitigated tumor growth. Notably, the combination of EGFR-CAR NK-92 cells with oHSV-1 resulted in more efficient killing of MDA-MB-231 tumor cells and significantly longer survival of tumor-bearing mice when compared to monotherapies. These results demonstrate that regional administration of EGFR-CAR NK-92 cells combined with oHSV-1 therapy is a potentially promising strategy to treat BCBMs.

SUBMITTER: Chen X 

PROVIDER: S-EPMC5053686 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.

Chen Xilin X   Han Jianfeng J   Chu Jianhong J   Zhang Lingling L   Zhang Jianying J   Chen Charlie C   Chen Luxi L   Wang Youwei Y   Wang Hongwei H   Yi Long L   Elder J Bradley JB   Wang Qi-En QE   He Xiaoming X   Kaur Balveen B   Chiocca E Antonio EA   Yu Jianhua J  

Oncotarget 20160501 19


Breast cancer brain metastases (BCBMs) are common in patients with metastatic breast cancer and indicate a poor prognosis. These tumors are especially resistant to currently available treatments due to multiple factors. However, the combination of chimeric antigen receptor (CAR)-modified immune cells and oncolytic herpes simplex virus (oHSV) has not yet been explored in this context. In this study, NK-92 cells and primary NK cells were engineered to express the second generation of EGFR-CAR. The  ...[more]

Similar Datasets

| S-EPMC10869753 | biostudies-literature
| S-EPMC5435599 | biostudies-literature
| S-EPMC4810253 | biostudies-literature
| S-EPMC8235327 | biostudies-literature
| S-EPMC8234451 | biostudies-literature
| S-EPMC5544283 | biostudies-literature
| S-EPMC7105799 | biostudies-literature
| S-EPMC2835221 | biostudies-other
| S-EPMC3961437 | biostudies-literature
| S-EPMC8562586 | biostudies-literature